Abstract
The emergence of the antiphospholipid syndrome (APS) over the last thirty-odd years has been one of the most striking developments in clinical autoimmunity. The identification of a pure or “primary” variant of the syndrome has been central to this story, not least in enabling us to establish the place of this remarkable condition in the wide spectrum of autoimmune disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis, type incidence and cause. JAMA 1952; 150: 467–473.
Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. [Review] [95 refs]. Prog Hemost Thromb 1972; 1: 75–95.
Bowie WEJ, Thompson JH, Pascuzzi CA, Owen CA. Thrombosis in SLE despite circulation anticoagulant. J Clin Invest 1963; 62: 413–430.
Margolius A, Jackson DP, Ratnoff OD. Circulation anticoagulants: a study of 40 cases and a review of the literature. Medicine (Baltimore) 1961; 40: 145–202.
Nilsson IM, Astedt B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant (“antithromboplastin”). Acta Med Scand 1975; 197 (3): 153–159.
Firkin BG, Howard MA, Radford N. Possible relationship between lupus inhibitor and recurrent abortion in young women [letter]. Lancet 1980; 2 (8190): 366.
Carreras LO, Defreyn G, Machin SJ, Vermylen J, Deman R, Spitz B et al. Arterial thrombosis, intrauterine death and “lupus” anticoagulant: detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981; 1 (8214): 244–246.
Yin ET, Gaston LW. Purification and kinetic studies on a circulating anticoagulant in a suspected case of lupus erythematosus. Thromb Diath Haemorrhag 1965; 14: 88–115.
Laurell AB, Nilsson IM. Hypergammaglobulinaemia, circulating anticoagulant and biologic false positive Wassermann reaction. J Lab Clin Med 1957; 49: 694–707.
Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 2 (8361): 1211–1214.
Violi F, Valesini G, Ferro D, Tincani A, Balestrieri G, Balsano F. Anticoagulant activity of anticardiolipin antibodies. Thromb Res 1986; 44 (4): 543–7.
Boey ML, Colaco CB, Gharavi AE, Elkon KB, Loizou S, Hughes GR. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br Med J 1983; 287 (6398): 1021–1023.
Hughes GR. Thrombosis, abortion, cerebral disease, and the lupus anticoagulant. Br Med J 1983; 287: 1088–1089.
Hughes GR. The anticardiolipin syndrome [editorial]. Clin Exp Rheumatol 1985; 3: 285–286.
Harris EN, Baguley E, Asherson RA, Hughes GRV. Clinical and serological features of the “antiphospholipid syndrome” (APS). Br J Rheumatol 1987; 26: 19.
Asherson RA. A “primary” antiphospholipid syndrome? J Rheumatol 1988; 15: 1742–1746.
Asherson RA, Baguley E, Pal C, Hughes GR. Antiphospholipid syndrome: five year follow up. Ann Rheum Dis 1991; 50: 805–810.
Mujic F, Cuadrado MJ, Lloyd M, Khamashta MA, Page G, Hughes GR. Primary antiphospholipid syndrome evolving into systemic lupus erythematosus. J Rheumatol 1995; 22: 1589–1592.
Andrews PA, Frampton G, Cameron JS. Antiphospholipid syndrome and systemic lupus erythematosus [letter; comment]. Lancet 1993; 342: 988–989.
Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients [see comments]. Am J Med 1994; 96: 3–9.
Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RH, Machin SJ, Barquinero J et al. The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine 1989; 68: 366–74.
Font J, Lopez-Soto A, Cervera R, Balasch J, Pallares L, Navarro M et al. The “primary” antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients. Autoimmunity 1991; 9: 69–75.
Loizou CG, Mackworth-Young C, Cofiner C, Walport MJ. Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis. Clin Exp Immunol 1990; 80: 171–176.
Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor [see comments]. Lancet 1990; 335: 1544–1547.
McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120–4124.
Harris EN, Pierangeli S. Anticardiolipin antibodies: specificity and function. [Review] [58 refs]. Lupus 1994; 3: 217–222.
Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457–462.
Roubey RA, Eisenberg RA, Harper MF, Winfield JB. “Anticardiolipin” autoantibodies recognize beta 2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954–960.
Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of anti-phospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods 1991; 143: 223–229.
Roubey RA. Immunology of the antiphospholipid antibody syndrome. [Review] [116 refs]. Arthritis Rheum 1996; 39: 1444–1454.
Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61: 684–692.
Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807–816.
Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512–9.
Arvieux J, Darnige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120–1125.
Godeau B, Piette JC, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997; 98: 873–879.
Panzer S, Gschwandtner ME, Hutter D, Spitzauer S, Pabinger I. Specificities of platelet autoantibodies in patients with lupus anticoagulants in primary antiphospholipid syndrome. Ann Hematol 1997; 74: 239–242.
Kertesz Z, Yu BB, Steinkasserer A, Haupt H, Benham A, Sim RB. Characterization of binding of human beta 2-glycoprotein Ito cardiolipin. Biochem J 1995; 310: 315–321.
Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995; 22: 1899–1906.
Najmey SS, Keil LB, Adib DY, DeBari VA. The association of antibodies to beta 2 glycoprotein I with the antiphospholipid syndrome: a meta-analysis. Ann Clin Lab Sci 1997; 27: 41–46.
Cabral AR, Cabiedes J, Alarcon-Segovia D. Antibodies to phospholipid-free beta 2-glycoprotein-I in patients with primary antiphospholipid syndrome. J Rheumatol 1995; 22: 1894–1898.
Day HM, Thiagarajan P, Ahn C, Reveille JD, Tinker KF, Arnett FC. Autoantibodies to beta 2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998; 25: 667–674.
Loizou S, Byron MA, Englert HJ, David J, Hughes GR, Walport MJ. Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in systemic lupus erythematosus. Quart J Med 1988; 68: 525–531.
Escalante A, Brey RL, Mitchell BD, Jr., Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995; 98: 559–565.
Viard JP, Amoura Z, Bach JF. Association of anti-beta 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus [see comments]. Am J Med 1992; 93: 181–186.
Lopez-Soto A, Cervera R, Font J, Bove A, Reverter JC, Munoz FJ et al. Isotype distribution and clinical significance of antibodies to cardiolipin, phosphatidic acid, phosphatidylinositol and phosphatidylserine in systemic lupus erythematosus: prospective analysis of a series of 92 patients. Clin Exp Rheumatol 1997; 15: 143–149.
Levine SR, Brey RL, Sawaya KL, Salowich-Palm L, Kokkinos J, Kostrzema B et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995; 38: 119–124.
Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456–459.
Alarcon-Segovia D, Perez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21: 275–286.
Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: a primary variant with antibodies to beta 2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med 1996; 101: 472–481.
Alarcon-Segovia D, Mestanza M, Cabiedes J, Cabral AR. The antiphospholipid/cofactor syndromes. II. A variant in patients with systemic lupus erythematosus with antibodies to /32-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. J Rheumatol 1997; 24: 1545–1551.
Piette JC, Wechsler B, Francis C, Godeau P. Systemic lupus erythematosus and the antiphospholipid syndrome: reflections about the relevance of ARA criteria [editorial] [see comments]. J Rheumatol 1992; 19: 1835–1837.
Piette JC, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary antiphospholipid syndrome [letter]. J Rheumatol 1993; 20: 1802–1804.
Johannsson EA, Niemi KM, Mustakillio KK. A peripheral vascular syndrome overlapping with SLE: recurrent venous thrombosis and hemorrhagic capillary proliferation with circulating anticoagulants and false-positive reactions for syphilis. Dermatologica 1977; 15: 257–267.
Alegre VA, Gastineau DA, Winkelmann RK. Skin lesions associated with circulating lupus anticoagulant. Br J Dermatol 1989; 120: 419–429.
Badui E, Solorio S, Martinez E, Bravo G, Enciso R, Barile L et al. The heart in the primary antiphospholipid syndrome. Arch Med Res 1995; 26: 115–120.
Coudray N, de Zuttere D, Bletry O, Piette JC, Wechsler B, Godeau P et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J 1995; 74: 531–535.
Hamsten A, Norberg R, Bjorkholm M, de Faire U, Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986; 1: 113–116.
APASS. The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischaemia. Stroke 1990; 21: 1268–1273.
Montalban J, Codina A, Ordi J, Vilardell M, Khamashta MA, Hughes GR. Antiphospholipid antibodies in cerebral ischemia. Stroke 1991; 22: 750–753.
Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990; 40: 1190–1196.
APASS. The Antiphospholipid Antibodies in Stroke Study Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993; 43: 2069–2073.
Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103: 33–37.
Inzelberg R, Korczyn AD. Lupus anticoagulant and late onset seizures [see comments]. Acta Neurol Scand 1989; 79: 114–118.
Sneddon IB. Cerebral vascular lesion in livedo reticularis. Br J Dermatol 1965; 77: 180–185.
Kalashnikova LA, Nasonov EL, Kushekbaeva AE, Gracheva LA. Anticardiolipin antibodies in Sneddon’s syndrome. Neurology 1990; 40: 464–467.
Asherson RA, Harris NE, Gharavi AE, Hughes GR. Systemic lupus erythematosus, antiphospholipid antibodies, chorea, and oral contraceptives [letter]. Arthritis Rheum 1986; 29: 1535–1536.
Lubbe WF, Walker EB. Chorea gravidarum associated with circulating lupus anticoagulant: successful outcome of pregnancy with prednisone and aspirin therapy. Case report. Br J Obstet Gynaecol 1983; 90: 487–490.
Goldstein SR. Embryonic death in early pregnancy: a new look at the first trimester. Obstet Gynecol 1994; 84: 294–297.
Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol 1996; 87: 489–493.
Silver RM, Porter TF, van Leeuween I, Jeng G, Scott JR, Branch DW. Anticardiolipin antibodies: clinical consequences of “low titers”. Obstet Gynecol 1996; 87: 494–500.
Aoki K, Hayashi Y, Hirao Y, Yagami Y. Specific antiphospholipid antibodies as a predictive variable in patients with recurrent pregnancy loss. Am J Reprod Immunol 1993; 29: 82–87.
Derue G, Englert HJ, Harris EN et al. Foetal loss in systemic lupus: association with anticardiolipin antibodies. J Obstet Gynaecol 1985; 5: 207–209.
Fanelli A, Bergamini C, Rapi S, Caldini A, Spinelli A, Buggiani A et al. Flow cytometric detection of circulating activated platelets in primary antiphospholipid syndrome. Correlation with thrombocytopenia and anticardiolipin antibodies. Lupus 1997; 6: 261–267.
Emmi L, Bergamini C, Spinelli A, Liotta F, Marchione T, Caldini A et al. Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. Ann N Y Acad Sci 1997; 823: 188–200.
Mackworth-Young CG, Loizou S, Walport MJ. Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder. Ann Rheum Dis 1989; 48: 362–367.
Alarcon-Segovia D, Sanchez-Guerrero J. Primary antiphospholipid syndrome [published erratum appears in J Rheumatol 1989 Jul;16(7):1014]. J Rheumatol 1989; 16: 482–488.
Asherson RA, Khamashta MA, Hughes GR. The hepatic complications of the antiphospholipid antibodies [editorial]. Clin Exp Rheumatol 1991; 9: 341–344.
Pomeroy C, Knodell RG, Swaim WR, Arneson P, Mahowald ML. Budd-Chiari syndrome in a patient with the lupus anticoagulant. Gastroenterology 1984; 86: 158–161.
Mor F, Beigel Y, Inbal A, Goren M, Wysenbeek AJ. Hepatic infarction in a patient with the lupus anticoagulant. Arthritis Rheum 1989; 32: 491–495.
Lee HJ, Park JW, Chang JC. Mesenteric and portal venous obstruction associated with primary antiphospholipid antibody syndrome [see comments]. J Gastroenterol Hepatol 1997; 12: 822–826.
Tatrai T, Kiss G, Sevcic K. Inferior vena cava thrombosis developing in primary antiphospholipid syndrome [Hungarian]. Dry Hetil 1996; 137: 135–137.
Asherson RA, George EN, Hughes GRV. Hypertension, renal artery stenosis and the “primary” antiphospholipid syndrome. J Rheumatol 1991; 18: 1413–1415.
Sonpal GM, Sharma A, Miller A. Primary antiphospholipid antibody syndrome, renal infarction and hypertension. J Rheumatol 1993; 20: 1221–1223.
Grottolo A, Ferrari V, Mariano M, Zambruni A, Tincani A, Del Bono R. Primary adrenal insufficiency, circulating lupus anticoagulant and anticardiolipin antibodies in a patient with multiple abortions and recurrent thrombotic episodes. Haematologica 1988; 73: 517–519.
Marie I, Levesque H, Heron F, Cailleux N, Borg JY, Courtois H. Acute adrenal failure secondary to bilateral infarction of the adrenal glands as the first manifestation of primary antiphospholipid antibody syndrome [letter]. Ann Rheum Dis 1997; 56: 567–568.
Takeuchi S, Obayashi T, Toyama J. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA. Heart 1998; 79: 96–98.
Nagai S, Horie Y, Akai T, Takeda S, Takaku A. Superior sagittal sinus thrombosis associated with primary antiphospholipid syndrome–case report [Review] [23 refs]. Neurol Med Chir 1998; 38: 34–39.
Sandoval J, Amigo MC, Barragan R, Izaguirre R, Reyes PA, Martinez-Guerra ML et al. Primary antiphospholipid syndrome presenting as chronic thromboembolic pulmonary hypertension. Treatment with thromboendarterectomy. J Rheumatol 1996; 23: 772–775.
Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 1990; 40: 1181–1189.
Keller E, Sommer T, Lutterbey G, Schild HH. Coincident arterial and venous cerebral thrombosis in primary antiphospholipid syndrome [German]. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1996; 165: 300–302.
Khoo KB, Long FL, Tuck RR, Allen RJ, Tymms KE. Cerebral venous sinus thrombosis associated with the primary antiphospholipid syndrome. Resolution with local thrombolytic therapy. [Review] [14 refs]. Med J Aust 1995; 162: 30–32.
Lockwood CJ, Reece EA, Romero R, Hobbins JC. Anti-phospholipid antibody and pregnancy wastage [letter]. Lancet 1986; 2: 742–743.
Cowchock S, Smith JB, Gocial B. Antibodies to phospholipids and nuclear antigens in patients with repeated abortions. Am J Obstet Gynecol 1986; 155: 1002–1010.
Unander AM, Norberg R, Hahn L, Arfors L. Anticardiolipin antibodies and complement in ninety-nine women with habitual abortion. Am J Obstet Gynecol 1987; 156: 114–119.
Petri M, Golbus M, Anderson R, Whiting OKQ, Corash L, Hellmann D. Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. Arthritis Rheum 1987; 30: 601–606.
Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997; 6: 509–513.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer-Verlag London
About this chapter
Cite this chapter
Vincent, T., Mackworth-Young, C. (2000). The Primary Antiphospholipid Syndrome. In: Khamashta, M.A. (eds) Hughes Syndrome. Springer, London. https://doi.org/10.1007/978-1-4471-3666-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-4471-3666-8_12
Publisher Name: Springer, London
Print ISBN: 978-1-85233-232-7
Online ISBN: 978-1-4471-3666-8
eBook Packages: Springer Book Archive